ReviewDiabetes, metabolic syndrome and obesity : targets and therapy2025
Advances in the Role of Stem Cell-Derived Exosomes in Diabetic Foot Wound Healing.
Review in Diabetes, metabolic syndrome and obesity : targets and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Hydrogels in Autoimmune Disease: A Comprehensive Review of Current Research and Clinical Potentials.International journal of nanomedicine · 2026Review
- Integrated platform for EV separation and controlled release based on gelatin microspheres for diabetic wound treatment.Regenerative biomaterials · 2026Article
- Advances in Stem Cell Therapy for Diabetic Foot Ulcers.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Review
- Exosomal non-coding RNAs: a new avenue for treating diabetic foot ulcers.Frontiers in molecular biosciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic hyperglycemia over a long period can lead to diabetes-related complications, of which diabetic foot ulcers continue to have a huge economic and social impact worldwide. Mesenchymal stem cell-derived exosomes (MSC-Exos) have demonstrated positive efficacy in the preclinical research and clinical trial phases of diabetic foot ulcer (DFU) treatment. In this review, we provide a brief overview of the properties of MSC-derived exosomes and their biological functions, summarize the therapeutic efficacy of Exos in the treatment of diabetic foot ulcers and its mechanism of action, and discuss innovative technologies including hydrogel scaffolds and 3D bioprinting to enhance the effectiveness of MSC - Exos in the treatment of diabetic foot ulcers. This paper also explores the application of innovative technologies such as hydrogel scaffolds and 3D bioprinting in enhancing the efficacy of MSC-Exos in the treatment of diabetic foot ulcers and highlights the key challenges faced in translating these advanced technologies from the laboratory to the clinic.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.